Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors

Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the company claims improves their specificity and minimizes off-target effects.